Drug Trial Radar · NCT07800871
FT839 in Autoimmune Diseases
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
446
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Oct 2028
Study completion Oct 2040
Sponsor
- Lead sponsor
- Fate TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.
Conditions
- ANCA-Associated Vasculitis (AAV)
- Idiopathic Inflammatory Myositis (IIM)
- Rheumatoid Arthritis (RA)
- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (SSc)
Interventions
FT839Biological
Single Intravenous (IV) infusion of FT839 administered on Day 1 and Day 4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of Dose-limiting Toxicity, Adverse Events, and Serious Adverse EventsTime frame: From enrollment to the end of the post-treatment follow-up at 2 years
- Phase 2: Change from baseline in Birmingham Vasculitis Activity ScoreTime frame: From enrollment to the end of the post-treatment follow-up at 2 years
- Phase 2: Change from baseline in Manual muscle testing-8Time frame: From enrollment to the end of the post-treatment follow-up at 2 years
- Phase 2: Change from baseline in Disease Activity Score using 28 joint counts and C-reactive protein (a composite measure)Time frame: From enrollment to the end of the post-treatment follow-up at 2 years
- Phase 2: Change from baseline in SLE Disease Activity Index 2000Time frame: From enrollment to the end of the post-treatment follow-up at 2 years
- Phase 2: Change from baseline in Modified Rodnan skin scoreTime frame: From enrollment to the end of the post-treatment follow-up at 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Providence Medical Foundation
Fullerton, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.